Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

GLP-1RA 的作用机制与减肥效果 截至 2025 年 1 月，已有三种肠促胰岛素类似物药物被批准用于治疗超重和肥胖，分别是利拉鲁肽、司美格鲁肽和替尔泊肽。其中，司美格鲁肽和替尔泊肽因每周给药一次且试验中平均体重减轻幅度更大（司美格鲁肽 15%，替尔泊肽 21% ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The result is "consistent with prior studies of injectable semaglutide and other GLP-1 receptor agonist," but a positive result is still a big deal, said principal investigator Darren K.

The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, one class of drugs—known as GLP-1 receptor agonists (GLP ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

"The GLP-1 agonist mimics the action of this naturally occurring hormone. After eating, blood sugars will rise, and these medications cause the pancreas to release more insulin which helps to ...

Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide ... Novo Nordisk markets its semaglutide drugs as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes and ...